JPH09501445A - 制御解放オキシブチニン配合物 - Google Patents
制御解放オキシブチニン配合物Info
- Publication number
- JPH09501445A JPH09501445A JP7522880A JP52288095A JPH09501445A JP H09501445 A JPH09501445 A JP H09501445A JP 7522880 A JP7522880 A JP 7522880A JP 52288095 A JP52288095 A JP 52288095A JP H09501445 A JPH09501445 A JP H09501445A
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- oxybutynin
- dosage form
- gelling agent
- solid dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.持効解放経口固形投与形態物であって、 鎮痙作用を提供するのに有効な量のオキシブチニンまたはその薬剤許容塩と、 ヘテロ多糖類ゴムおよび環境流体に曝されたときに前記ヘテロ多糖類ゴムを架 橋することができるホモ多糖類ゴムからなり前記ヘテロ多糖類ゴムの前記ホモ多 糖類ゴムに対する比が約1:3乃至約3:1であるゲル化剤約20乃至約60重 量%と、前記ゲル化剤と架橋することができるとともに投与形態物が環境流体に 曝されたときにゲル強度を高めることができる有効量の薬剤許容カチオン架橋剤 と、単糖類、二糖類、多価アルコールおよびこれらの混合物よりなる群から選ば れる不活性薬剤希釈剤とからなる持効解放マトリックスとを備え、前記オキシブ チニンの前記ゲル化剤に対する比が約1:2乃至約1:25であり、前記環境流 体に曝されたときに前記オキシブチニンの持効解放を行なうことを特徴とする持 効解放経口固形投与形態物。 2.前記オキシブチニンの前記ゲル化剤に対する比が重量で約1:5乃至約1: 15であることを特徴とする請求の範囲第1項に記載の経口固形投与形態物。 3.前記ヘテロ多糖類ゴムはキサンタンゴムからなり、前記ホモ多糖類ゴムはい なご豆ゴムからなることを特徴とする請求の範囲第1項に記載の経口固形投与形 態物。 4.前記カチオン架橋剤はアルカリ金属またはアルカリ土類金属の硫酸塩、塩化 物、硼酸塩、臭化物、くえん酸塩、酢酸塩または乳酸塩からなることを特徴とす る請求の範囲第1項に記載の経口固形投与形態物。 5.前記カチオン架橋剤は硫酸カルシウムからなることを特徴とする請求の範囲 第1項に記載の経口固形投与形態物。 6.前記持効解放賦形剤は更にアルキルセルロース、アクリルおよびメタクリル 酸エステルのコーポリマ、ワックス、セラック、ゼイン、水素化植物油およびこ れらの任意の混合物よりなる群から選ばれ、環境流体に曝されたときに前記ゲル 化剤の水和を緩慢にするのに有効な量の疎水性物質を含むことを特徴とする請求 の範囲第1項に記載の経口固形投与形態物。 7.前記疎水性物質はエチルセルロースであることを特徴とする請求の範囲第6 項に記載の経口固形投与形態物。 8.前記持効解放マトリックスは約1乃至約20重量%の前記疎水性物質を含む ことを特徴とする請求の範囲第6項に記載の経口固形投与形態物。 9.タブレットであることを特徴とする請求の範囲第1項に記載の経口固形投与 形態物。 10.約1乃至約10重量%の微結晶セルロースを更に備えることを特徴とする 請求の範囲第1項に記載の経口固形投与形態物。 11.前記オキシブチニンは約5乃至約20mgの量が含まれることを特徴とす る請求の範囲第1項に記載の経口固形投与形態物。 12.前記持効解放賦形剤は、重量で、20%乃至約60%のゲル化剤と、約1 乃至約20重量%のカチオン架橋剤と、約20%乃至約79%の不活性希釈剤と からなることを特徴とする請求の範囲第1項に記載の経口固形投与形態物。 13.前記持効解放マトリックスは、重量で、約25%乃至約50パーセントの ゲル化剤と、約5乃至約15重量パーセントのカチオン架橋剤と、約35%乃至 約70パーセントの不活性希釈剤とからなることを特徴とする請求の範囲第1項 に記載の経口固形投与形態物。 14.前記持効解放マトリックスは、重量で、約25%乃至約35パーセントの ゲル化剤と、約5乃至約15パーセントのカチオン架橋剤と、約50乃至約70 パーセントの不活性希釈剤とからなることを特徴とする請求の範囲第1項に記載 の経口固形投与形態物。 15.人間の患者に経口投与されたときに約24時間オキシブチニンの有効血液 レベルを提供することを特徴とする請求の範囲第1項に記載の経口固形投与形態 物。 16.オキシブチニンの固形経口持効解放配合物の製造方法であって、 ヘテロ多糖類ゴムおよび環境流体に曝されたときに前記ヘテロ多糖類ゴムを架 橋することができるホモ多糖類ゴムからなり前記ヘテロ多糖類ゴムの前記ホモ多 糖類ゴムに対する比が約1:3乃至約3:1であるゲル化剤約20乃至約60重 量パーセントと、前記ゲル化剤と架橋しかつ環境流体に曝されたときにゲル強度 を高めるのに有効な量のカチオン架橋剤と、不活性薬剤希釈剤とからなる持効解 放マトリックスを調製する工程と、 オキシブチニンのゲル化剤に対する比が重量で約1:2乃至約1:25となる ように前記持効解放マトリックスをオキシブチニンまたはその薬剤許容塩と混合 する工程と、 持効解放マトリックスとオキシブチニンとの前記混合物を圧縮して、鎮痙作用 を発揮するのに必要な量のオキシブチニンを有し、環境流体に曝されたときに約 24時間オキシブチニンの持効解放を行なうタブレットを形成する工程とを備え ることを特徴とする固形経口持効解放配合物の製造方法。 17.前記持効解放賦形剤に約1乃至約20重量パーセントの前記カチオン架橋 剤を含ませる工程を更に備えることを特徴とする請求の範囲第16項に記載の方 法。 18.前記持効解放賦形剤を疎水性物質で粒状化する工程を更に備えることを特 徴とする請求の範囲第17項に記載の方法。 19.前記カチオン架橋剤は硫酸カルシウムであり、前記疎水性物質はエチルセ ルロースからなることを特徴とする請求の範囲第17項に記載の方法。 20.オキシブチニンを用いて患者を治療する方法であって、 ヘテロ多糖類ゴムおよび環境流体に曝されたときに前記ヘテロ多糖類ゴムを架 橋することができるホモ多糖類ゴムからなり前記ヘテロ多糖類ゴムの前記ホモ多 糖類ゴムに対する比が約1:3乃至約3:1であるゲル化剤約20乃至約60重 量パーセントと、前記ゲル化剤と架橋しかつ胃腸の流体に曝されたときに配合物 のゲル強度を高めるのに有効な量のカチオン架橋剤と、不活性薬剤希釈剤とから なる持効解放マトリックスを調製する工程と、 オキシブチニンのゲル化剤に対する比が重量で約1:2乃至約1:25となる ように持効解放マトリックスをオキシブチニンまたはその薬剤許容塩と混合する 工程と、 持効解放マトリックスとオキシブチニンとの前記混合物を圧縮して、鎮痙作用 を発揮するのに必要な量のオキシブチニンを有し、胃腸流体に曝されたときに約 24時間オキシブチニンの持効解放を行なうタブレットを形成する工程と、 前記タブレットを人間の患者に24時間の間隔で投与する工程とを備えること を特徴とする治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/206,416 US5399359A (en) | 1994-03-04 | 1994-03-04 | Controlled release oxybutynin formulations |
US08/206,416 | 1994-03-04 | ||
PCT/US1994/002926 WO1995023593A1 (en) | 1994-03-04 | 1994-03-18 | Controlled release oxybutynin formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004340786A Division JP2005126444A (ja) | 1994-03-04 | 2004-11-25 | 制御放出オキシブチニン製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09501445A true JPH09501445A (ja) | 1997-02-10 |
JP3699117B2 JP3699117B2 (ja) | 2005-09-28 |
Family
ID=22766272
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52288095A Expired - Fee Related JP3699117B2 (ja) | 1994-03-04 | 1994-03-18 | 制御解放オキシブチニン配合物 |
JP2004340786A Pending JP2005126444A (ja) | 1994-03-04 | 2004-11-25 | 制御放出オキシブチニン製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004340786A Pending JP2005126444A (ja) | 1994-03-04 | 2004-11-25 | 制御放出オキシブチニン製剤 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5399359A (ja) |
EP (1) | EP0700284B1 (ja) |
JP (2) | JP3699117B2 (ja) |
CN (1) | CN1111404C (ja) |
AT (1) | ATE222753T1 (ja) |
AU (1) | AU676556B2 (ja) |
CA (1) | CA2161103C (ja) |
DE (1) | DE69431247T2 (ja) |
DK (1) | DK0700284T3 (ja) |
ES (1) | ES2180574T3 (ja) |
FI (1) | FI113337B (ja) |
HU (1) | HUT72981A (ja) |
IL (1) | IL112637A (ja) |
PT (1) | PT700284E (ja) |
WO (1) | WO1995023593A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009149691A (ja) * | 2001-03-13 | 2009-07-09 | Penwest Pharmaceuticals Co | 時間治療(chronotherapeutic)投与形態 |
US7943176B2 (en) | 2001-10-09 | 2011-05-17 | Apogepha Arzneimittel Gmbh | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
JP2017100971A (ja) * | 2015-11-30 | 2017-06-08 | 株式会社ファンケル | 錠剤 |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
WO1996012477A1 (en) * | 1994-10-21 | 1996-05-02 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
US6124355A (en) * | 1995-05-22 | 2000-09-26 | Guittard; George V. | Oxybutynin therapy |
US6262115B1 (en) | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
AU2068797A (en) * | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
ES2141044B1 (es) * | 1997-02-26 | 2001-02-01 | Alza Corp | Terapia con oxibutinina. |
US20040062799A1 (en) * | 1997-09-29 | 2004-04-01 | Ayer Atul D. | Therapeutic composition and delivery system for administering drug |
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
US6087396A (en) * | 1998-10-05 | 2000-07-11 | Situs Corporation | Oxybutynin formulations and method of use |
NZ511900A (en) * | 1999-09-30 | 2003-06-30 | Penwest Pharmaceuticals Co | Sustained release matrix systems for highly soluble drugs |
US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
DE60219478T2 (de) * | 2001-07-06 | 2008-01-03 | Endo Pharmaceuticals Inc. | Orale gabe von 6-hydroxy-oxymorphon als analgetikum |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
KR20040045485A (ko) * | 2001-10-08 | 2004-06-01 | 썬 파마슈티컬 인더스트리스 리미티드 | 항경련제가 간격을 두고 배치된 약물전달계 |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
CA2494281A1 (en) * | 2002-08-02 | 2004-02-12 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
WO2005011682A1 (ja) * | 2003-08-04 | 2005-02-10 | Kyorin Pharmaceutical Co., Ltd. | 経口徐放性錠剤 |
KR100782918B1 (ko) * | 2003-09-19 | 2007-12-07 | 펜웨스트 파머슈티칼즈 컴파니 | 지연 방출성 제형 |
JP2007519608A (ja) * | 2003-09-19 | 2007-07-19 | ペンウェスト ファーマシューティカルズ カンパニー | 時間治療用剤形 |
JP5610663B2 (ja) * | 2003-11-04 | 2014-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | トロスピウムの1日1回剤形 |
US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
DE602005020462D1 (de) | 2004-08-25 | 2010-05-20 | Essentialis Inc | Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen |
NZ561330A (en) | 2005-03-15 | 2009-06-26 | Htc Sweden Ab | Method and tool for maintenance of hard surfaces, and a method for manufacturing such a tool |
US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
WO2007059372A2 (en) * | 2005-11-09 | 2007-05-24 | St. Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
EP3545958A1 (en) | 2006-01-05 | 2019-10-02 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
AU2008272923A1 (en) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
US20090076144A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched bazedoxifene |
EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
JP5819329B2 (ja) * | 2010-03-09 | 2015-11-24 | アルカーメス ファーマ アイルランド リミテッド | アルコール耐性腸溶性医薬組成物 |
WO2011117884A1 (en) * | 2010-03-22 | 2011-09-29 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
EP2819675A4 (en) | 2012-02-27 | 2015-07-22 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF |
WO2013142482A1 (en) | 2012-03-20 | 2013-09-26 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
US20150133516A1 (en) | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
CA2966907C (en) | 2014-11-14 | 2021-09-07 | Essentialis, Inc. | Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome |
CA3029602A1 (en) | 2015-07-02 | 2017-01-05 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for delivery of mirna and methods for treatment of cancer |
DE102015014581A1 (de) * | 2015-11-12 | 2017-05-18 | Nele Schmidt | Prolamine enthaltende Gele, Verfahren zu ihrer Herstellung und ihre Verwendung |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4303691A (en) * | 1977-11-09 | 1981-12-01 | Anderson, Clayton & Co. | Proteinaceous food product |
US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
JPS5630485A (en) * | 1979-08-21 | 1981-03-27 | Sansho Kk | Heat insulation composition for heating and cooling |
BE902605A (fr) * | 1985-06-06 | 1985-09-30 | Therabel Res S A N V | Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition. |
US4795642A (en) * | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
CA1272922A (en) * | 1986-06-03 | 1990-08-21 | Peter William Berry | Drug delivery device, its preparation and use |
GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
DE3714074A1 (de) * | 1987-04-28 | 1988-11-10 | Hoechst Ag | Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage |
US4824675A (en) * | 1987-07-13 | 1989-04-25 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
US4857331A (en) * | 1988-03-31 | 1989-08-15 | Warner-Lambert Company | Sugarless pectin delivery system |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
US5207932A (en) * | 1989-07-20 | 1993-05-04 | Chubb National Foam, Inc. | Alcohol resistant aqueous film forming firefighting foam |
US5271943A (en) * | 1989-10-27 | 1993-12-21 | Scott Health Care | Wound gel compositions containing sodium chloride and method of using them |
US5215756A (en) * | 1989-12-22 | 1993-06-01 | Gole Dilip J | Preparation of pharmaceutical and other matrix systems by solid-state dissolution |
US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
JPH04273818A (ja) * | 1991-02-28 | 1992-09-30 | Kissei Pharmaceut Co Ltd | 経皮投与製剤 |
HU209251B (en) * | 1992-03-13 | 1994-04-28 | Synepos Ag | Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons |
ZA933349B (en) * | 1992-05-13 | 1994-06-15 | Alza Corp | Transdermal administration of oxybutynin |
JP2646170B2 (ja) * | 1992-06-24 | 1997-08-25 | 日本ヘキスト・マリオン・ルセル株式会社 | 徐放性塩酸オキシブチニン製剤 |
US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
-
1994
- 1994-03-04 US US08/206,416 patent/US5399359A/en not_active Expired - Lifetime
- 1994-03-18 DK DK94913918T patent/DK0700284T3/da active
- 1994-03-18 CA CA002161103A patent/CA2161103C/en not_active Expired - Fee Related
- 1994-03-18 PT PT94913918T patent/PT700284E/pt unknown
- 1994-03-18 DE DE69431247T patent/DE69431247T2/de not_active Expired - Fee Related
- 1994-03-18 HU HU9503054A patent/HUT72981A/hu unknown
- 1994-03-18 AT AT94913918T patent/ATE222753T1/de not_active IP Right Cessation
- 1994-03-18 ES ES94913918T patent/ES2180574T3/es not_active Expired - Lifetime
- 1994-03-18 AU AU65888/94A patent/AU676556B2/en not_active Ceased
- 1994-03-18 EP EP94913918A patent/EP0700284B1/en not_active Expired - Lifetime
- 1994-03-18 WO PCT/US1994/002926 patent/WO1995023593A1/en active IP Right Grant
- 1994-03-18 JP JP52288095A patent/JP3699117B2/ja not_active Expired - Fee Related
-
1995
- 1995-02-14 IL IL11263795A patent/IL112637A/en active IP Right Grant
- 1995-03-03 CN CN95100475A patent/CN1111404C/zh not_active Expired - Fee Related
- 1995-11-01 FI FI955215A patent/FI113337B/fi active
-
2004
- 2004-11-25 JP JP2004340786A patent/JP2005126444A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009149691A (ja) * | 2001-03-13 | 2009-07-09 | Penwest Pharmaceuticals Co | 時間治療(chronotherapeutic)投与形態 |
US7943176B2 (en) | 2001-10-09 | 2011-05-17 | Apogepha Arzneimittel Gmbh | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
JP2017100971A (ja) * | 2015-11-30 | 2017-06-08 | 株式会社ファンケル | 錠剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1111404C (zh) | 2003-06-18 |
IL112637A0 (en) | 1995-05-26 |
WO1995023593A1 (en) | 1995-09-08 |
IL112637A (en) | 1999-01-26 |
EP0700284B1 (en) | 2002-08-28 |
FI113337B (fi) | 2004-04-15 |
DE69431247D1 (de) | 2002-10-02 |
EP0700284A4 (en) | 1996-11-06 |
AU676556B2 (en) | 1997-03-13 |
MX9501193A (es) | 1998-07-31 |
US5399359A (en) | 1995-03-21 |
HUT72981A (en) | 1996-06-28 |
ES2180574T3 (es) | 2003-02-16 |
FI955215A (fi) | 1995-11-01 |
EP0700284A1 (en) | 1996-03-13 |
ATE222753T1 (de) | 2002-09-15 |
FI955215A0 (fi) | 1995-11-01 |
JP3699117B2 (ja) | 2005-09-28 |
PT700284E (pt) | 2003-01-31 |
DE69431247T2 (de) | 2003-01-02 |
JP2005126444A (ja) | 2005-05-19 |
DK0700284T3 (da) | 2003-01-06 |
CA2161103C (en) | 1999-12-07 |
AU6588894A (en) | 1995-09-18 |
CN1111507A (zh) | 1995-11-15 |
HU9503054D0 (en) | 1996-01-29 |
CA2161103A1 (en) | 1995-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3699117B2 (ja) | 制御解放オキシブチニン配合物 | |
US5399358A (en) | Sustained release formulations for 24 hour release of metroprolol | |
US5399362A (en) | Once-a-day metoprolol oral dosage form | |
KR100321489B1 (ko) | 고용량의불용성약물용서방성매트릭스 | |
JP4077886B2 (ja) | 不溶性薬剤の持効性ヘテロ分散ヒドロゲル系 | |
EP0360562B1 (en) | Directly compressible sustained release excipient | |
JPH08512061A (ja) | 持続放出性賦形剤 | |
MXPA95001193A (es) | Formulaciones de oxibutinina de liberacioncontrolada | |
MXPA96000024A (en) | Form of oral dosing of metoprolol one time | |
MXPA94008792A (en) | Sustained release formulations for 24 hours of metopro release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040825 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050418 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050707 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |